Your browser doesn't support javascript.
loading
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni, Andrea; Azevedo, Sergio; Rubio-Viqueira, Belen; Rodríguez-Abreu, Delvys; Alatorre-Alexander, Jorge; Smit, Hans J M; Yu, Jinming; Syrigos, Konstantinos; Trunzer, Kerstin; Patel, Hina; Tolson, Jonathan; Cardona, Andres; Perez-Moreno, Pablo D; Newsom-Davis, Tom.
Afiliação
  • Ardizzoni A; Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy andrea.ardizzoni@aosp.bo.it.
  • Azevedo S; Oncology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Rubio-Viqueira B; Department of Medical Oncology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain.
  • Rodríguez-Abreu D; Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas, Canarias, Spain.
  • Alatorre-Alexander J; Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, Mexico.
  • Smit HJM; Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands.
  • Yu J; Department of Radiation Oncology, Shandong Cancer Hospital, affiliated to Shandong University, Jinan, Shandong, China.
  • Syrigos K; 3rd Department of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece.
  • Trunzer K; Department of Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.
  • Patel H; Department of Safety Science Oncology, Genentech Inc, South San Francisco, California, USA.
  • Tolson J; Department of Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.
  • Cardona A; Department of Product Development Biometrics, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.
  • Perez-Moreno PD; Department of Product Development, Genentech Inc, South San Francisco, California, USA.
  • Newsom-Davis T; Department of Oncology, Chelsea and Westminster Hospital, London, UK.
J Immunother Cancer ; 9(3)2021 03.
Article em En | MEDLINE | ID: mdl-33737339
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Anticorpos Monoclonais Humanizados / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Anticorpos Monoclonais Humanizados / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália País de publicação: Reino Unido